Clayton I. Duncan

Chairman & Chief Executive Officer at Pamlico BioPharma, Inc.

Clayton I. Duncan

Clayton I. Duncan

Chairman & Chief Executive Officer at Pamlico BioPharma, Inc.

Overview
Career Highlights

Otologic Pharmaceutics, Inc.
Synereca Pharmaceuticals, Inc.
Pamlico BioPharma, Inc.

RelSci Relationships

244

Number of Boards

7

Birthday

1950

Age

68

Relationships
RelSci Relationships are individuals Clayton I. Duncan likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Synereca Pharmaceuticals, Inc.

Relationship likelihood: Strong

President & Chief Operating Officer at Pamlico BioPharma, Inc.

Relationship likelihood: Strong

President at Oklahoma Medical Research Foundation

Relationship likelihood: Strong

Executive Chairman at Novelion Therapeutics, Inc.

Relationship likelihood: Strong

Chief Scientific Officer at Synereca Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at Synereca Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Otologic Pharmaceutics, Inc.

Relationship likelihood: Strong

Manager at PEC Investment Properties LLC

Relationship likelihood: Strong

Co-Founder at Otologic Pharmaceutics, Inc.

Relationship likelihood: Strong

Trustee at Texas Christian University

Relationship likelihood: Strong

Paths to Clayton I. Duncan
Potential Connections via
Relationship Science
You
Clayton I. Duncan
Chairman & Chief Executive Officer at Pamlico BioPharma, Inc.
Education
M.B.A

The University of North Carolina at Chapel Hill also known as UNC, UNC-Chapel Hill, Chapel Hill, North Carolina, or simply Carolina is a coeducational public research university located in Chapel Hill, North Carolina, United States. North Carolina has been consistently ranked among the highest ranked universities in the United States and is one of the original eight Public Ivy schools that provide an Ivy League experience for a public schooling price. After being chartered in 1789, the university first began enrolling students in 1795, which allows it to be one of three schools to claim the title of the oldest public university in the United States.

MA

The University of California, Santa Barbara (commonly referred to as UC Santa Barbara or UCSB) is a public research university and one of the 10 general campuses of the University of California system. The main campus is located on a 1,022-acre (414 ha) site near Goleta, California, United States, 8 miles (13 km) from Santa Barbara and 100 miles (160 km) northwest of Los Angeles. Tracing its roots back to 1891 as an independent teachers' college, UCSB joined the University of California system in 1944 and is the third-oldest general-education campus in the system. UCSB traces its origins back to the Anna Blake School which was founded in 1891 and offered training in home economics and industrial arts. The Anna Blake School was taken over by the state in 1909 and became the Santa Barbara State Normal School. Intense lobbying by an interest group in the City of Santa Barbara, led by Thomas Storke and Pearl Chase, persuaded the State Legislature, Governor Earl Warren, and the Regents of the University of California to move the State College over to the more research-oriented University of California system in 1944. The State College system sued to stop the takeover, but the Governor did not support the suit. A state initiative was passed, however, to stop subsequent conversions of State Colleges to University of California campuses. From 1944 to 1958 the school was known as Santa Barbara College of the University of California, before taking on its current name. When the vacated Marine Corps training station in Goleta was purchased for the rapidly-growing college, Santa Barbara City College moved into the vacated State College buildings.

Career History
Chairman & Chief Executive Officer
2014 - Current

Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK.

Chairman & Chief Executive Officer
2009 - Current

Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. It focuses on compounds that enhance the activity of Colistin against gram-negative bacteria without enhancing its toxicity. The company was founded in 2009 by Clayton I. Duncan, Stephen B. Bocckino and Bennett W. Love and is headquartered in Oklahoma City, OK.

Chairman & Chief Executive Officer
Current

Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK.

Boards & Committees
Chairman & Chief Executive Officer
2009 - Current

Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. It focuses on compounds that enhance the activity of Colistin against gram-negative bacteria without enhancing its toxicity. The company was founded in 2009 by Clayton I. Duncan, Stephen B. Bocckino and Bennett W. Love and is headquartered in Oklahoma City, OK.

Chairman & Chief Executive Officer
Current

Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK.

Chairman & Chief Executive Officer
Current

Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK.

Transactions
Details Hidden

Synereca Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Accele Biopharma, Inc. raised money in a private placement transaction

Details Hidden

Accele Venture Partners I LP raised money in a private placement transaction

Investments
Details Hidden

Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. It focuses on compounds that enhance the activity of Colistin against gram-negative bacteria without enhancing its toxicity. The company was founded in 2009 by Clayton I. Duncan, Stephen B. Bocckino and Bennett W. Love and is headquartered in Oklahoma City, OK.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Clayton I. Duncan. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Clayton I. Duncan's profile does not indicate a business or promotional relationship of any kind between RelSci and Clayton I. Duncan.